Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2022-04-28 Report Publication Anno…
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
EUROBIO SCIENTIFIC : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2021
Report Publication Announcement Classification · 99% confidence The document is titled "MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2021" (Making available the 2021 Annual Financial Report). It explicitly states that Eurobio Scientific has made available and filed its annual financial report for the year ended December 31, 2021, with the AMF (Autorité des Marchés Financiers). However, the document itself is very short (2429 characters) and serves primarily to announce that the report is available on the company's website. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report has been published or is available elsewhere points towards a Report Publication Announcement (RPA) rather than the full Annual Report (10-K) itself. The next financial event mentioned is the AGM, but this document is about the Annual Financial Report publication.
2022-04-28 French
EUROBIO SCIENTIFIC : Rapport financier annuel 2021
Annual Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER ANNUEL 2021' (Annual Financial Report 2021) for Eurobio Scientific. It contains a comprehensive management report ('Rapport de gestion'), detailed financial analysis, governance information, and board disclosures for the fiscal year ending December 31, 2021. As it is the primary annual reporting document covering company activity and financial performance, it is classified as a 10-K. FY 2021
2022-04-28 French
Eurobio Scientific s’associe au Dr. Nino Guy Cassuto pour le développement d’un nouveau test PCR dans le cadre de la fertilité masculine
Regulatory Filings Classification · 99% confidence The document is a press release dated April 26, 2022, announcing a strategic agreement between Eurobio Scientific and Dr. Nino Guy Cassuto for the development and commercialization of a new PCR test related to male fertility. It details the product, market potential, and includes forward-looking statements and contact information. This type of announcement, focusing on a specific business development (licensing agreement, product pipeline update) rather than routine financial results (ER, IR) or mandatory regulatory filings (10-K, DEF 14A), is best classified as a general corporate announcement. Since there is no specific category for 'Business Development Announcement' or 'Press Release', and it is not a short notice about a report publication (the document is substantial), the most appropriate fallback category is 'Regulatory Filings' (RNS), which often serves as a catch-all for significant, non-standard corporate news released to the market.
2022-04-26 French
Eurobio Scientific partners with Dr. Nino Guy Cassuto for the development of a new PCR test for male fertility
Regulatory Filings Classification · 100% confidence The document is a press release dated April 26, 2022, announcing a strategic partnership and the development of a new PCR test for male fertility. It details business strategy, market growth, and product pipeline, which are typical components of an Earnings Release (ER) or a general corporate update. It is not a full Annual Report (10-K), a formal Audit Report (AR), or a transcript (CT). Since it announces key business developments and financial context (market size, growth), it fits best as an Earnings Release (ER) or potentially a Regulatory Filing (RNS) if it were purely informational. However, the content strongly suggests a business/financial update released outside of a formal quarterly report filing, making ER the most appropriate fit for key highlights. It also mentions the 'Annual shareholders' meeting' date, but the document itself is not the AGM material or the proxy statement. Given the nature of announcing a significant business development and market context, ER is the primary classification.
2022-04-26 English
Eurobio Scientific: CE mark for new proprietary test for the detection of Omicron BA.x, BA.2 and Delta variants of SARS-CoV-2
Regulatory Filings Classification · 95% confidence The document is a press release dated April 14, 2022, announcing that Eurobio Scientific has received the CE mark for its new proprietary COVID-19 diagnostic test (EBX 048). It details the test's capabilities (detecting Omicron BA.x, BA.2, and Delta variants) and its immediate availability. This type of announcement, focusing on a specific product milestone or operational update rather than comprehensive financial results (like 10-K or IR) or management changes (MANG), fits best under a general regulatory or news announcement category. Since it is a specific, non-financial operational update (product approval), and not a standard earnings release (ER) or a formal regulatory filing like a 10-K, it is classified as a Regulatory Filing (RNS) as the most appropriate general announcement category, although it shares characteristics with an Earnings Release in format. However, the core content is a product/regulatory achievement, not financial performance highlights. The document also mentions the upcoming Annual Shareholders' Meeting date, but the primary content is the CE mark announcement. Given the options, RNS serves as the best fit for a significant, non-financial, regulatory/operational news release.
2022-04-14 English
Eurobio Scientific : Marquage CE du nouveau test propriétaire pour la détection des variants Omicron BA.x, BA.2 et Delta du SARS-CoV-2
Regulatory Filings Classification · 95% confidence The document is a press release dated April 14, 2022, announcing that Eurobio Scientific has received CE marking for its new proprietary COVID-19 variant detection test (EBX 048). It details the technical capabilities of the test (RT-PCR, identifying Omicron BA.x, BA.2, and Delta variants) and its immediate availability. This type of announcement, focusing on a specific product development, regulatory approval (CE marking), and immediate market availability, is characteristic of a general corporate news release or regulatory update that doesn't fit the strict definitions of an Earnings Release (ER), Interim Report (IR), or a specific financial filing like 10-K or DEF 14A. Since it is a specific, non-financial regulatory/product announcement, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous official announcements not covered by other specific codes. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal financial report.
2022-04-14 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.